[{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"PreveCeutical Medical"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sirona Biochem Corp"},{"orgOrder":0,"company":"Sernova","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sernova"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the collaboration, AstraZeneca will explore the use of Sernova’s Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications.
Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
The patent application, entitled “Use of Ketamine in the Treatment of Diabetes and Obesity,” identifies protein bindings and interactions with ketamine leading to the discovery of ketamine as a potential treatment for Type 2 diabetes and obesity.
The company has identified a promising modified delivery vector ready for possible pre-clinical experiments based on stable siRNA (small interfering ribonucleic acid) incorporation within the delivery vehicle.